CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting

CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting

13th May 2024

Belfast, UK, 10 May 2024 – CV6 Therapeutics (‘CV6’) is a clinical-stage drug development company targeting Uracil-DNA biology to transform the treatment of cancer and inflammatory diseases. CV6 will be presenting details of their ongoing CV6-168 Phase 1a clinical trial at the 2024 ASCO Annual Meeting to be held at McCormick Pace in Chicago, USA on May 31st to June 4th.


Details of the CV6-168 Phase 1a trial will be presented as part of the Trials in Progress poster session in:

– McCormick Place, Chicago
– Hall A
– June 1st between 9 and 12 local time (CDT)
– Poster abstract number: TPS3170
– Poster Board Number:  310A


CV6-168 is a first-in-class specific DNA uracilation agent that selectively targets the enzyme dUTPase and induces cancer cell DNA uracilation when used in combination with the thymidylate synthase inhibitor class of standard-of-care therapies (5-FU and pemetrexed) resulting in cancer cell death while simultaneously stimulating the immune system.
The poster will present details of the UK multi-centre Phase 1a clinical trial that is now actively recruiting across four leading cancer hospitals that form part of the UK Experimental Cancer Medicine Centre (ECMC) network: Belfast, Glasgow, Newcastle, and the Royal Marsden in London.


The Phase 1a trial is evaluating CV6-168 in combination with infusional 5-FU and folinic acid to treat advanced malignancies. Initially, the trial will focus on safety, pharmacokinetics, identifying optimal dosing levels, and assessing initial indications of anti-cancer activity in up to 51 patients (ISRCTN12434145).

Details of the trial will be presented as part of the ‘Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology’ track within the “Trials in Progress” poster session. The poster will be presented by Prof. Vicky Coyle, Principal Investigator of the lead site in Belfast and Prof. Richard Wilson from the Glasgow site and the trial Chief Investigator. Also in attendance will be Dr. Robert (Bob) Ladner, CEO and Founder of the trial sponsor, CV6 Therapeutics.

“We are excited that our clinical trial was selected for presentation at this year’s ASCO Annual Meeting.” said Robert Ladner. “CV6-168 represents a new class of agent, targeting uracil-DNA biology in cancer cells and is an exciting opportunity to significantly improve treatment options for patients across multiple cancer indications, including some of the most difficult-to-treat cancers that currently lack effective therapies.” “We encourage anyone who is interested in this area of cancer therapeutics and wants to know more about CV6-168 and the clinical trial to stop by the poster and say hello.”

Founded in 1964, the American Society of Clinical Oncology is the world’s leading professional organization for physicians and oncology professionals caring for and improving the lives of people with cancer. The ASCO Annual Meeting is the largest gathering of these professionals in the world.


CV6 Therapeutics

CV6 Therapeutics is a clinical stage drug development company developing value-based, first-in-class medications that are scalable to address global unmet medical needs in the oncology and inflammatory disease markets. To learn more about CV6 Therapeutics and its product pipeline including CV6-168, or to contact us, click here:


To arrange a meeting or discuss more about CV6-168 and what CV6 Therapeutics is doing, please feel free to contact Robert (Bob) Ladner using the details below.

Dr Robert Ladner, CEO / / +447500444287